Neurology companies develop therapies, diagnostics and technologies that improve understanding and treatment of disorders affecting the brain, spinal cord and nervous system. The field addresses some of the most complex challenges in modern medicine.
This category includes companies working on:
Browse 114 UK neurology companies below.
AI-powered retinal biomarker platform for early detection of eye and brain disease
Novai is a biotechnology company commercialising DARC (Detection of Apoptosing Retinal Cells), a retinal biomarker platform combining a fluorescent biologic with an AI image analysis algorithm to detect single-cell apoptosis in the retina in vivo. FDA and MHRA approved as an exploratory biomarker, DARC enables early…
Tau-targeting therapeutics and diagnostics for neurodegenerative disease
TauRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments and diagnostics for Alzheimer's disease and related neurodegenerative disorders. Its pipeline centres on tau aggregation inhibitors, which target the pathological accumulation of tau protein implicated in dementia. The company's…
Non-surgical drug therapy for spinal cord injury recovery
NeuroSolv Therapeutics is a preclinical-stage biotechnology company developing a non-surgical two-part therapy for spinal cord injury. The proposed mechanism combines enzymatic removal of perineuronal nets on spinal cord neurons with treatment of signal-blocking glial scar tissue, enabling new synaptic connections to…
Clinical-stage medicines for alcohol use disorder and PTSD
Solvonis Therapeutics is a clinical-stage biopharmaceutical company developing treatments for addiction and mental health disorders. Its lead programme is in Phase III for severe alcohol use disorder, with additional programmes addressing moderate to severe alcohol use disorder, post-traumatic stress disorder and…
Preclinical orexin-1 addiction therapies and CNS drug discovery
TheraCryf is an AIM-listed biotechnology company developing small-molecule therapies for addiction and other neuropsychiatric conditions. Its lead orexin-1 receptor antagonist programme is completing preclinical toxicology and regulatory preparations for a first-in-human Phase 1 trial in Australia. An Australian CRO…
Mitochondrial transplantation platform to restore cellular energy and regeneration
Recondria Therapeutics is a developer of a mitochondrial transplantation platform designed to restore cellular energy, accelerate tissue recovery and support regenerative medicine. The company's approach involves isolating healthy mitochondria and delivering them to damaged cells to restore ATP production and cellular…
Cannabinoid medicines, neuroscience and oncology drug development
Jazz Pharmaceuticals is a global biopharmaceutical company focused on medicines for neuroscience and oncology. Its UK operations, centred at Kent Science Park in Sittingbourne, form the heart of its global cannabinoid manufacturing and research activities, inherited through its 2021 acquisition of GW Pharmaceuticals…
Specialist CRO for oncology, rare disease, and neurology clinical trials
Evestia Clinical is a global specialist contract research organisation providing full-service and functional clinical trial support to biotech and pharmaceutical companies. The company offers clinical operations, site and project management, regulatory affairs, biostatistics, pharmacovigilance, and medical writing…
AI-driven natural product discovery for neurological therapeutics
Pangea Bio is a clinical-stage biotechnology company developing small molecule therapeutics for neurological and neuropsychiatric disorders. Its proprietary AI platform screens natural and plant-derived chemical space, integrating ethnobotanical data with machine learning to identify novel CNS drug candidates with…
Ion channel drug discovery platform for rare CNS disorders
Autifony Therapeutics is a clinical-stage UK biotech developing small molecule modulators of Kv3 voltage-gated potassium channels for rare genetic CNS disorders. Lead programmes target Fragile X syndrome and rare myoclonic epilepsy syndromes, with preclinical work extending to schizophrenia, hearing loss, and…
Transcription factor-targeting drug discovery for neurodegeneration
Scripta Therapeutics is an Oxford-based biotech company developing disease-modifying therapeutics by mapping and modulating transcription factor networks. Its platform integrates AI, imaging, and patient-derived models in a lab-in-the-loop workflow to identify compounds that restore healthy cellular states. The…
National institute researching dementia and neurodegenerative disease across the UK
The UK Dementia Research Institute is the UK's leading national institute dedicated to transforming outcomes for people affected by dementia and neurodegenerative conditions. Its central Hub at University College London coordinates seven research Centres hosted across leading UK universities, working towards new…
Antibody immunotherapy targeting toxic tau for neurodegenerative disease
TauC3 Biologics is a preclinical biopharmaceutical company developing an antibody-based immunotherapy that targets tauC3, a toxic, truncated form of the tau protein implicated in neurodegenerative disease. Its lead candidate, TBL-100, is a humanized monoclonal antibody developed with LifeArc, designed to selectively…
Therapeutics and blood biomarker tests for ALS
Vesalic develops therapeutic and diagnostic approaches for amyotrophic lateral sclerosis (ALS), focusing on the potential role of metabolic dysfunction outside the nervous system. Its preclinical programmes include a treatment candidate designed to address toxic cargo carried by exosomes to motor neurons, alongside a…